Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022202 · ClinicalTrials.gov registry record
Breast Cancer Genome Guided Therapy Study (BEAUTY)
A clinical trial of Invasive Breast Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- 140
- Enrollment target
- 2
- Study locations
NCT02022202 is a study of Invasive Breast Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 140 participants, above the 125-participant average among 19 other Invasive Breast Cancer trials with a reported enrollment target (12% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT02022202, a study of Invasive Breast Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies.
Conditions Studied
Study Locations (2)
Arizona
- Mayo Clinic campus in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2012-03-03 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02022202
The ClinicalTrials.gov registry entry for NCT02022202 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 125-participant average among 19 other Invasive Breast Cancer trials with a reported enrollment target (12% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Invasive Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02022202 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02022202 about?
NCT02022202 is a clinical study titled "Breast Cancer Genome Guided Therapy Study (BEAUTY)". The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies.
What is the current status of trial NCT02022202?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2012-03-03. Estimated completion is 2020-12-31.
What conditions does trial NCT02022202 study?
This clinical trial studies the following conditions: Invasive Breast Cancer.
Who is sponsoring clinical trial NCT02022202?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02022202 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
RECRUITING · Phase 1
-
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.